1. Introduction {#sec1-diseases-06-00004}
===============

It has been reported that pharmacological treatment related to chronic heart failure (CHF), such as beta-adrenergic receptor blockers (beta-blockers) and angiotensin-converting enzyme inhibitors (ACE-I), not only alleviates symptoms but also improves prognosis, particularly through the suppression of neurohormonal factors. However, in older patients with deteriorated and severe CHF, exercise tolerance is limited by the symptoms, and the rehospitalization rate due to acute exacerbation and the mortality rate are still high even with the currently available optimal treatment \[[@B1-diseases-06-00004],[@B2-diseases-06-00004],[@B3-diseases-06-00004]\]. Therefore, it is necessary to attempt to treat each patient with CHF individually rather than providing uniform treatment.

The number of older adults with coexisting chronic obstructive pulmonary disease (COPD) and heart failure with reduced ejection fraction (HFrEF) has recently reached global epidemic levels, with each of the diseases affecting \>10 million patients. The reported prevalence of COPD in patients with HFrEF ranges widely, from 11% to 52% in North America and from 9% to 41% in Europe \[[@B4-diseases-06-00004],[@B5-diseases-06-00004]\]. These two common diseases exert adverse effects on one another, reduce the patient health-related quality of life (HRQoL) and exercise tolerance, and considerably increase morbidity and mortality. We focused on this unique but large population and attempted to find treatments that could overcome the limitations of existing CHF therapies.

Tiotropium is a once-daily, long-acting inhaled anticholinergic drug that provides improvements in airflow and hyperinflation for at least 24 h, thus reducing dyspnea and improving exercise tolerance and HRQoL \[[@B6-diseases-06-00004],[@B7-diseases-06-00004]\]. Therefore, it is a commonly prescribed therapeutic agent for patients with COPD. Recently, inhalation of tiotropium has also been reported to suppress the occurrence of congestive heart failure and the onset of myocardial infarction, and to reduce the risk of cardiovascular events and mortality \[[@B8-diseases-06-00004],[@B9-diseases-06-00004]\]. Furthermore, tiotropium was reported to improve COPD without exacerbating the coexisting CHF, as reflected in the decrease in both the brain natriuretic peptide (BNP) and serum norepinephrine (NE) levels \[[@B10-diseases-06-00004]\]. On the basis of these previous reports, we investigated in the present study whether anticholinergic bronchodilator therapy reduces the severity of both COPD and heart failure.

2. Patients and Methods {#sec2-diseases-06-00004}
=======================

2.1. Participants {#sec2dot1-diseases-06-00004}
-----------------

The inclusion criteria for this study were as follows: (1) stable COPD, confirmed with spirometry as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee \[[@B11-diseases-06-00004]\]; (2) chronic left-sided systolic heart failure of New York Heart Association (NYHA) functional class I or II, as defined by the American College of Cardiology/American Heart Association guidelines \[[@B12-diseases-06-00004]\]; (3) reduced left ventricular (LV) ejection fraction (LVEF) of \<40%; and (4) high level of serum BNP (\>100 pg/mL) with optimal medical therapy for at least three months before enrollment. The patients had already taken oral diuretics, ACE-I, angiotensin receptor blockers (ARBs), calcium-channel blockers (CCBs), and beta-blockers. Their previous medication remained unchanged throughout the study period.

2.2. Study Protocol {#sec2dot2-diseases-06-00004}
-------------------

The enrolled participants were randomly divided into two groups, A and B, following a 2-week baseline period. The participants inhaled 18 μg tiotropium once daily between 6:00 a.m. and 8:00 a.m. through a dry powder inhaler device (HandiHaler^®^; Boehringer Ingelheim, Ingelheim am Rhein, Germany) \[[@B13-diseases-06-00004]\]. Inhalation of tiotropium took place after the patients were given adequate instruction and training by professional nurses. Continuation of inhalation was confirmed at each outpatient examination. Participants who could not continue the inhalation therapy were excluded from this clinical trial. The participants in group A received tiotropium once a day for 28 days and underwent observation for another 28 days. The participants in group B were observed without inhalation for 28 days and then received tiotropium for 28 days ([Figure 1](#diseases-06-00004-f001){ref-type="fig"}). During these protocols, the other medications taken by the participants were unchanged. We measured the pulse oximetry oxygen saturation (SpO~2~), pulmonary function, 6-min walk distance (6MWD), echocardiographic parameters, and laboratory markers on days 1, 29, and 56. The study protocol was approved by an independent ethics committee, and written informed consent was obtained from all patients.

### 2.2.1. Pulmonary Function {#sec2dot2dot1-diseases-06-00004}

We evaluated pulmonary function by using spirometry, which was conducted between 9:00 a.m. and 11:00 a.m. in accordance with American Thoracic Society (ATS) standards. The predicted normal values for forced expiratory volume (FEV) and forced vital capacity (FVC) were derived from standard equations \[[@B14-diseases-06-00004]\].

### 2.2.2. Six-Minute Walk Distance {#sec2dot2dot2-diseases-06-00004}

We measured the distance the patient was able to walk, self-paced, on a flat, hard surface in a period of 6 min. This test was conducted between 9:00 a.m. and 11:00 a.m., per ATS guidelines \[[@B15-diseases-06-00004]\].

### 2.2.3. Echocardiography {#sec2dot2dot3-diseases-06-00004}

Echocardiographic examination was performed by skilled echocardiographers who were blinded to the purpose of the study. The echocardiographic parameters of LV systolic and diastolic function were obtained. The conventional parameters of LV dimension and LVEF were also obtained and measured using a modified Simpson method.

### 2.2.4. Laboratory Measurements {#sec2dot2dot4-diseases-06-00004}

During a 30-min supine rest, blood samples for biochemistry and complete blood count were drawn from patients who had fasted since 7:00 p.m. the previous night. Plasma BNP and NE levels were measured with a specific immunoradiometric assay using commercial kits (Shionogi, Osaka, Japan). Enzyme-linked immunosorbent assay was performed. The normal ranges of BNP and NE with these measurements are ≤18.6 pg/mL and 15--57 pg/mL, respectively.

### 2.2.5. Statistical Analysis {#sec2dot2dot5-diseases-06-00004}

We presented data as numbers (percentages) for categorical variables and as means ± standard deviations for continuous variables in the tables. Obtained parameters were compared during different conditions with repeated-measures analysis of variance followed by Tukey's post hoc test to establish the statistical significance of tests. We also tested the relationship between the percentage decrease of BNP and the absolute increase of FEV1.0 by using Pearson's correlation coefficients. A two-sided *p*-value of \<0.05 was considered statistically significant. All analyses were performed using SAS statistical software (version 9.2; SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-diseases-06-00004}
==========

3.1. Patients' Characteristics {#sec3dot1-diseases-06-00004}
------------------------------

Fifty-two consecutive outpatients diagnosed as having COPD complicated by HFrEF met the inclusion criteria and were recruited for this study. Patients with a history of asthma (*n* = 2), allergic rhinitis (*n* = 1), or allergies (*n* = 1); an increased total eosinophil count (*n* = 1); or orthopedic disorder (*n* = 5) were excluded. Patients in GOLD stage III (severe; FEV1.0/FVC \< 70% and 30% ≤ FEV1.0(%predict) \< 50%) and in GOLD stage IV (very severe; FEV1.0/FVC \< 70% and 30% \> FEV1.0(%predict)) were not enrolled (*n* = 2).

At the time of enrollment into this study, no patient had clinical evidence of fluid overload. All patients were classified as having NYHA I (*n* = 13) or II (*n* = 27) CHF. Twenty-two patients had ischemic heart disease (55%) and 13 had hypertensive heart disease (32.5%). The mean LVEF, arterial pressure, and plasma BNP level were 36.5 ± 2.0%, 120 ± 7/80 ± 8 mmHg, and 372 ± 105 pg/mL, respectively. The mean FEV1.0 and 6MWD were 1.56 ± 0.18 L and 405 ± 62 m, respectively. Fifteen patients (37.5%) had GOLD stage I/mild COPD (FEV1.0/FVC \< 70% and FEV1.0(%predict) ≥ 80%), and 25 patients (62.5%) had GOLD stage II/moderate COPD (FEV1.0/FVC \< 70% and 50% ≤ FEV1.0(%predict) \< 80%). Twenty-two patients received beta-blockers, all patients received either ACE-I or ARB, three patients received a CCB, and 32 patients received diuretics. After randomization, there was no significant difference between the two groups ([Table 1](#diseases-06-00004-t001){ref-type="table"}). During the study period, no patient dropped out owing to discontinuation of tiotropium inhalation or any adverse events, and there were no unexpected visits.

3.2. Clinical Effects of Tiotropium for Patients with HFrEF and COPD {#sec3dot2-diseases-06-00004}
--------------------------------------------------------------------

### 3.2.1. Blood Pressure {#sec3dot2dot1-diseases-06-00004}

In both groups, blood pressure significantly decreased after the inhalation of tiotropium, although medications were not changed during the study period ([Table 2](#diseases-06-00004-t002){ref-type="table"} and [Table 3](#diseases-06-00004-t003){ref-type="table"}).

### 3.2.2. Six-Minute Walk Distance {#sec3dot2dot2-diseases-06-00004}

Treatment with tiotropium inhalation improved the 6MWD from 405 ± 57 to 424 ± 46 m (*p* \< 0.01) in group A and from 399 ± 74 to 422 ± 58 m (*p* \< 0.01) in group B, and termination of inhalation reduced the distance in group A to 405 ± 63 m (*p* \< 0.01) ([Figure 2](#diseases-06-00004-f002){ref-type="fig"}).

### 3.2.3. Pulmonary Function {#sec3dot2dot3-diseases-06-00004}

FEV1.0 and FVC were elevated by the inhalation of tiotropium in both groups, whereas termination of inhalation therapy decreased FEV1.0 and FVC in group A ([Table 2](#diseases-06-00004-t002){ref-type="table"} and [Table 3](#diseases-06-00004-t003){ref-type="table"}).

### 3.2.4. Cardiac Function {#sec3dot2dot4-diseases-06-00004}

In both groups, LVEF improved (*p* \< 0.01) and diastolic LV diameter (LVDd) increased (*p* \< 0.01); in addition, the pressure gradient between the right atrial and right ventricle chamber (PG(RA-RV)) significantly decreased without any change to the diameter of the inferior vena cava ([Table 2](#diseases-06-00004-t002){ref-type="table"} and [Table 3](#diseases-06-00004-t003){ref-type="table"}).

### 3.2.5. Plasma BNP and NE Levels {#sec3dot2dot5-diseases-06-00004}

Although there was no significant hemodynamic change, tiotropium inhalation decreased the plasma BNP and NE levels in both groups. Termination of inhalation therapy increased the plasma BNP and NE levels in group A ([Figure 3](#diseases-06-00004-f003){ref-type="fig"} and [Table 2](#diseases-06-00004-t002){ref-type="table"}).

### 3.2.6. Relation between Change in FEV and LVDd {#sec3dot2dot6-diseases-06-00004}

Tiotropium inhalation increased not only FEV1.0 but also LVDd in both groups; however, the systolic LV diameter did not change ([Table 2](#diseases-06-00004-t002){ref-type="table"} and [Table 3](#diseases-06-00004-t003){ref-type="table"}). Although it was not significant, there was a tendency for the changes in LVDd and FEV1.0 to be related (r = 0.57, *p* = 0.096).

### 3.2.7. Relationship between Change in FEV and BNP {#sec3dot2dot7-diseases-06-00004}

In the present study, we demonstrated that anticholinergic bronchodilator therapy decreases the plasma BNP level in patients with HFrEF complicated by COPD, and there was a significant relationship between the percentage decrease of the plasma BNP level and the absolute change of FEV1.0 resulting from tiotropium inhalation (r = −0.68, *p* \< 0.01) in both groups ([Figure 4](#diseases-06-00004-f004){ref-type="fig"}). However, there was no relationship between plasma NE levels and FEV1.0.

3.3. Adverse Effects {#sec3dot3-diseases-06-00004}
--------------------

Several adverse events occurred during the study period. Dry mouth occurred in 12 patients, nasal congestion in four patients, nose bleeding in three patients, and constipation in one patient. The proportion of patients who experienced adverse effects during the course of the study period was similar in both groups. The only adverse effect that differed significantly between the tiotropium inhalation and observation groups was dry mouth, which occurred in nine patients (22.5%) in the tiotropium inhalation group and in three patients (7.5%) during the observation period. No adverse events occurred that led to the discontinuation of the study.

4. Discussion {#sec4-diseases-06-00004}
=============

In the present study, we demonstrated the clinical effects of tiotropium inhalation therapy for patients with mild to moderate COPD. As in many reports thus far, we found that the treatment improved pulmonary function, particularly increasing FEV1.0 and consequently increasing 6MWD. Furthermore, we demonstrated that tiotropium inhalation therapy increased the LVEF, decreased the PG(RA-RV), and decreased the plasma BNP level, which indicate that the treatment reduced the severity of heart failure.

4.1. Possible Mechanisms by Which Anticholinergic Bronchodilator Improves HFrEF {#sec4dot1-diseases-06-00004}
-------------------------------------------------------------------------------

It has been shown that the larger the degree of pulmonary emphysema, the smaller the left ventricle, and the lower the FEV1.0, the smaller the left ventricle, which indicate that hyperinflation of the lungs affects the size of the heart and is associated with an extended disturbance of the heart \[[@B16-diseases-06-00004]\]. In patients with HFrEF, the contraction force of the LV is reduced because the cardiac output is usually maintained by LV dilatation. The excess expiratory load in patients with COPD increases the intrathoracic pressure and pushes the right ventricle, resulting in reduced gradient for venous return \[[@B17-diseases-06-00004]\]. In addition, the marked hyperinflation associated with COPD may reduce the speed and volume of LV filling because of competition for intrathoracic space \[[@B18-diseases-06-00004]\]. Thus, the effect of decreased cardiac output is remarkable in patients with HFrEF. The primary mechanism for improvement likely involves reduced obstruction, improved gradient for venous return, and a mild deflation, thereby improving cardiac filling pressures. Indeed, a prior article reported that tiotropium inhalation improved diastolic function and reduced LV end-diastolic pressure, as assessed with tissue Doppler echocardiography \[[@B10-diseases-06-00004]\].

Skeletal muscle alterations in patients with COPD include decreased muscle strength and mass, with reduced cross-sectional area, fiber shift with atrophy of type I oxidative fibers, and increase in glycolytic type IIa and IIb fibers accompanied by an increase in glycolytic activities and a decrease in oxidative enzymatic activities \[[@B19-diseases-06-00004],[@B20-diseases-06-00004]\]. Muscle atrophy contributes to respiratory muscle fatigue, which causes patients with CHF to discontinue exercising before they have exhausted their cardiac reserves \[[@B21-diseases-06-00004]\]. Furthermore, respiratory muscle weakness increases neurohormonal activities. Thus, improvement of air trapping resulting from inhalation of tiotropium decreases the inspiratory load and results in reduced fatigue on inspiration and improved exercise capacity.

We investigated the changes in SpO~2~ and found that tiotropium inhalation therapy improved oxygen delivery to the organs and muscles of the body at rest, which indicates that bronchodilator therapy improves the speed of oxygen delivery to the skeletal muscles during exercise. Consequently, increased oxygen delivery might suppress neurohormonal activities.

4.2. Sustained Effects after Termination of Tiotropium {#sec4dot2-diseases-06-00004}
------------------------------------------------------

After the termination of tiotropium inhalation, the PG(RA-RV) and plasma NE levels remained suppressed. Because the drug effects of tiotropium are clearly disappearing after the termination of inhalation therapy, these phenomena must be explained by the fact that the pathology of heart failure remains stable. Thus, as pulmonary function and hemodynamics improved during the administration of tiotropium therapy, the promotion of neurohormonal factors and inflammation are alleviated, and this good condition is sustained. However, it is unclear how long the beneficial effect lasts after termination, and it is presumed that it will eventually return to the state before administration. In fact, these data were slightly worse than those during tiotropium inhalation ([Table 2](#diseases-06-00004-t002){ref-type="table"} and [Table 3](#diseases-06-00004-t003){ref-type="table"}).

4.3. Safety of Tiotropium in Patients with HFrEF {#sec4dot3-diseases-06-00004}
------------------------------------------------

We observed no adverse effect of tiotropium inhalation therapy other than dry mouth in the present study. Beta-stimulant as a bronchodilator was reported to activate the neurohormonal system and to exacerbate CHF \[[@B22-diseases-06-00004]\]. However, tiotropium use was not associated with any cardiac safety concerns, as defined by electrocardiographic evaluations in placebo-controlled clinical trials \[[@B23-diseases-06-00004]\]. Furthermore, tiotropium was reported to suppress the activation of the sympathetic nervous system \[[@B24-diseases-06-00004]\] and to not increase the risk of cardiac events \[[@B22-diseases-06-00004],[@B25-diseases-06-00004]\]. Indeed, we observed that tiotropium inhalation therapy resulted in no adverse events, such as tachycardia, atrial fibrillation, or exacerbation of CHF.

4.4. Study Limitations {#sec4dot4-diseases-06-00004}
----------------------

In this study, we investigated patients with compensated heart failure with a reduced LVEF of \<40%; no data exist on heart failure with a preserved LVEF of \>40%. Although we investigated patients with mild to moderate ambulatory COPD, no data exist on HFrEF complicated by severe or very severe COPD. Because the study period was only two months long, whether inhalation of tiotropium influences mortality in this population is unknown. Clinical trials are needed to investigate the long-term prognosis on larger and more varied populations with multicenter implementation.

4.5. Clinical Implications {#sec4dot5-diseases-06-00004}
--------------------------

Dyspnea and loss of exercise capacity are symptoms of both COPD and HFrEF, and cause a reduction in HRQoL. When administrated to patients with COPD, tiotropium proved to improve cardiac function and reduce the severity of heart failure, as well as improved pulmonary function, resulting in improved HRQoL in patients with compensated HFrEF complicated by mild to moderate COPD. Although the total management in this specific but large population is still controversial, anticholinergic inhalation therapy is suggested as a potentially effective therapy.

5. Conclusions {#sec5-diseases-06-00004}
==============

In the present study, we demonstrated that anticholinergic bronchodilator therapy not only improved pulmonary function but also reduced the severity of heart failure in patients with compensated HFrEF complicated by mild to moderate COPD.
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diseases-06-00004-t001_Table 1

###### 

Patient characteristics.

  -----------------------------------------------------------------------------------------------------------------------------------
                                       All (*n* = 40)   Group A\                               Group B\
                                                        (Tiotropium + Observation; *n* = 20)   (Observation + Tiotropium; *n* = 20)
  ------------------------------------ ---------------- -------------------------------------- --------------------------------------
  Age, years                           70 ± 8           70 ± 7                                 70 ± 9

  Male, no. (%)                        23 (57.5)        11 (55)                                12 (60)

  Etiology of heart failure, no. (%)                                                           

  Ischemic heart disease               22 (55)          12 (60)                                10 (50)

  Hypertensive heart disease           13 (32.5)        6 (30)                                 7 (45)

  Others                               5 (12.5)         2 (10)                                 3 (15)

  NYHA class, no. (%)                                                                          

  I                                    13 (32.5)        7 (35)                                 6 (30)

  II                                   27 (67.5)        13 (65)                                14 (70)

  FEV1.0(%predict)                     77.9 ± 5.4       78.1 ± 5.7                             77.7 ± 5.7

  FEV1.0/FVC, %                        59.3 ± 5.0       59.3 ± 5.3                             59.2 ± 5.0

  Heart rate, beats/min                74.5 ± 5         73 ± 6                                 76 ± 5

  Systolic BP, mmHg                    120 ± 7          120 ± 6                                119 ± 9

  Diastolic BP, mmHg                   80 ± 8           79 ± 10                                81 ± 7

  LVEF, %                              36.5 ± 2.0       36.3 ± 2.4                             36.6 ± 1.8

  BNP, pg/mL                           372 ± 105        374 ± 94                               369 ± 119

  Medications, no. (%)                                                                         

  Beta-blockers                        22 (55)          11 (55)                                11 (55)

  ACE-I or ARB                         40 (100)         20 (100)                               20 (100)

  CCB                                  3 (7.5)          1 (5)                                  2 (10)

  Diuretics                            30 (75)          16 (80)                                14 (70)
  -----------------------------------------------------------------------------------------------------------------------------------

NYHA = New York Heart Association, FEV = forced expiratory volume, FVC = forced vital capacity, BP = blood pressure, LVEF = left ventricular ejection fraction, BNP = brain natriuretic peptide, beta-blocker = beta-adrenergic receptor blocker, ACE-I = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, CCB = calcium-channel blocker.

diseases-06-00004-t002_Table 2

###### 

Group A: tiotropium + observation.

                          Day 1         Day 29          Day 56         ANOVA
  ----------------------- ------------- --------------- -------------- ---------
  Systolic BP, mmHg       120 ± 6       115 ± 5 §       118 ± 4 ¶      \<0.01
  Diastolic BP, mmHg      79 ± 10       75 ± 9 ¶        74 ± 9 §       \<0.01
  Heart rate, bpm         73 ± 6        66 ± 5 ¶        68 ± 4 ¶       \<0.05
  BW, kg                  59.5 ± 13.7   59.0 ± 13.6     59.3 ± 13.5    NS
  SpO~2~, %               96.2 ± 1.7    97.0 ± 1.3 ¶    96.3 ± 1.8     \<0.01
  Respiratory function                                                 
  FEV1.0, L               1.56 ± 0.11   1.74 ± 0.16 §   1.51 ± 0.15    \<0.001
  FEV1.0(%predict), %     78.1 ± 5.7    87.2 ± 7.9 §    75.7 ± 7.4     \<0.001
  FVC, L                  2.64 ± 0.14   2.75 ± 0.13 §   2.55 ± 0.13    \<0.001
  FEV/FVC, %              59.3 ± 5.3    63.6 ± 6.4 §    59.5 ± 6.0     \<0.001
  Echocardiography                                                     
  LVDd, mm                57.3 ± 3.7    59.3 ± 3.6 ¶    56.2 ± 3.2     \<0.05
  LVDs, mm                49.5 ± 66.9   48.3 ± 4.2      48.0 ± 3.6     NS
  LVEF, %                 36.3 ± 2.4    41.8 ± 5.9 §    37.8 ± 7.8     \<0.01
  PG(RA-RV), mmHg         18.9 ± 4.8    16.7 ± 4.3 §    16.5 ± 5.1 §   \<0.05
  IVC, mm                 9.7 ± 1.8     9.6 ± 1.7       9.5 ± 1.6      NS
  Laboratory testing                                                   
  BNP, pg/mL              374 ± 94      263 ± 92 §      293 ± 78       \<0.001
  Norepinephrine, pg/mL   821 ± 251     468 ± 203 §     501 ± 191 ¶    \<0.001

The shaded part of the table indicates the periods of inhalation of tiotropium. § = *p* \< 0.01, ¶ = *p* \< 0.05 vs. before inhalation, respectively; 6MWD = 6-min walk distance, BP = blood pressure, bpm = beats per minute, BW = body weight, SpO~2~ = arterial oxygen saturation, FEV = forced expiratory volume, FVC = forced vital capacity, LVDd = diastolic left ventricular diameter, LVDs = systolic left ventricular diameter, LVEF = left ventricular ejection fraction, PG(RA-RV) = pressure gradient between the right atrial and right ventricular chamber, IVC = diameter of the inferior vena cava, BNP = brain natriuretic peptide, ANOVA = repeated-measures analysis of variance, NS = no significant change.

diseases-06-00004-t003_Table 3

###### 

Group B: observation + tiotropium.

                          Day 1         Day 29        Day 56          ANOVA
  ----------------------- ------------- ------------- --------------- ---------
  Systolic BP, mmHg       119 ± 9       118 ± 8       113 ± 7 §       \<0.01
  Diastolic BP, mmHg      81 ± 7        80 ± 7        75 ± 7 ¶        \<0.05
  Heart rate, bpm         76 ± 5        73 ± 4        68 ± 4 ¶        \<0.01
  BW, kg                  62.1 ± 13.4   61.9 ± 13.5   61.9 ± 13.6     NS
  SpO~2~, %               95.6 ± 1.1    96.6 ± 1.1    97.8 ± 0.8      \<0.01
  Respiratory function                                                
  FEV1.0, L               1.55 ± 0.11   1.60 ± 0.12   1.75 ± 0.18 §   \<0.001
  FEV1.0(%predict), %     77.7 ± 5.7    80.0 ± 6.0    87.4 ± 8.9 §    \<0.001
  FVC, L                  2.63 ± 0.12   2.64 ± 0.13   2.75 ± 0.11 §   \<0.001
  FEV/FVC, %              59.2 ± 5.0    60.6 ± 5.0    63.6 ± 5.7 §    \<0.001
  Echocardiography                                                    
  LVDd, mm                57.4 ± 3.1    57.1 ± 3.1    59.0 ± 3.1 ¶    \<0.05
  LVDs, mm                49.1 ± 6.2    49.5 ± 4.2    48.7 ± 3.8      NS
  LVEF, %                 36.6 ± 1.8    35.7 ± 3.8    41.6 ± 3.8 §    \<0.01
  PG(RA-RV), mmHg         19.6 ± 5.1    18.7 ± 5.2    16.5 ± 4.3 ¶    \<0.05
  IVC, mm                 9.5 ± 1.4     9.7 ± 1.6     9.5 ± 2.2       NS
  Laboratory testing                                                  
  BNP, pg/mL              369 ± 119     358 ± 110     246 ± 101 §     \<0.001
  Norepinephrine, pg/mL   826 ± 248     747 ± 241     446 ± 107 ¶     \<0.001

The shaded part of the table indicates the periods of inhalation of tiotropium. § = *p* \< 0.01, ¶ = *p* \< 0.05 vs. before inhalation, respectively; 6MWD = 6-min walk distance, BP = blood pressure, bpm = beats per minute, BW = body weight, SpO~2~ = arterial oxygen saturation, FEV = forced expiratory volume, FVC = forced vital capacity, LVDd = diastolic left ventricular diameter, LVDs = systolic left ventricular diameter, LVEF = left ventricular ejection fraction, PG(RA-RV) = pressure gradient between the right atrial and right ventricular chamber, IVC = diameter of the inferior vena cava, BNP = brain natriuretic peptide, ANOVA = repeated-measures analysis of variance, NS = no significant change.
